Merck & Co. Soars in Q3 2026: Record Revenue, Landmark Clinical Milestones

Share
Merck & Co. Soars in Q3 2026: Record Revenue, Landmark Clinical Milestones


Merck & Co., a leading pharmaceutical company, has reported impressive third-quarter results for 2026, with revenue hitting $18.1 billion. The company's strong performance is driven by the success of new products, particularly in oncology and animal health.

In a conference call on October 29, 2026, Merck & Co.'s Chairman and CEO, Rob Davis, highlighted the company's progress, stating that "2026 continues to be a year of substantial progress for our company." He emphasized the disciplined execution of their strategy over the past few years, which has led to meaningful clinical, regulatory, and commercial results.

One of the key highlights of Merck & Co.'s Q3 2026 performance is the significant contribution from new products. The company's oncology business, in particular, has shown impressive growth, with notable achievements including the first positive phase III results from their TroFuse program for sac-TMT in advanced or recurrent endometrial cancer.

The ESMO meeting last weekend showcased potential practice-changing advances for several innovative programs, with positive data shared on sac-TMT's potential in lung cancer and other tumor types. Additionally, a landmark validation of a therapeutic cancer vaccine with positive phase III data was presented for intismeran autogene as an adjuvant treatment for certain patients with melanoma.

In ophthalmology, Merck & Co. presented results from the BRUNELLO study evaluating remigromig in diabetic macular edema, a significant milestone for their rapidly advancing retinal disease portfolio. The company also reported encouraging phase IIb results in HS and looked forward to advancing their TL1A development program.

The clinical and commercial progress made by Merck & Co. underlines the ongoing transformation of their business and provides greater visibility into the trajectory of their emerging and expansive new product portfolio. With numerous significant readouts still to occur over the coming years, the company's momentum extends across multiple therapeutic areas and modalities.

Rob Davis expressed his confidence in the future of Merck & Co., stating that "the breadth of these achievements strengthens my confidence in the future of our company and our ability to deliver long-term value for patients and shareholders." The company's solid performance, driven by new product launches and clinical milestones, bodes well for their continued growth beyond the KEYTRUDA LOE period.

Read more